
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZDHHC13 (zDHHC palmitoyltransferase 13) encodes a predicted palmitoyltransferase located in the endoplasmic reticulum. The protein is predicted to have magnesium ion transmembrane transporter activity and palmitoyltransferase activity, indicating potential roles in membrane-associated protein lipid modification and ion transport. ZDHHC13 is also involved in positive regulation of canonical NF-kappaB signal transduction. Its precise molecular mechanisms remain incompletely characterized.
A human esophageal cancer cell line established from a poorly differentiated squamous cell carcinoma of the upper cervical esophagus in a 49-year-old woman after radiotherapy. KYSE-150 carries amplified c-erb-B and cyclin D1 oncogenes and has been reported to produce tumors in nude mice. The cell line has been extensively characterized and is included in large-scale cancer cell line resources.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 5
Reference Transcript: NM_019028
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?